Clinuvel Pharmaceuticals (ASX:CUV) Total Receivables: A$16.58 Mil (As of Dec. 2025)


ASX:CUV Clinuvel Pharmaceuticals Ltd ASX:CUV
86 GF Score
Price A$10.25
GF Value A$17.73
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals Total Receivables?

Clinuvel Pharmaceuticals ASX:CUV -0.10% 86 Total Receivables is A$16.58 Mil as of Dec. 2025. GuruFocus rates ASX:CUV with a GF Score™ of 86/100 and a GF Value™ of A$17.73 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Clinuvel Pharmaceuticals's Total Receivables for the quarter that ended in Dec. 2025 was A$16.58 Mil.

Clinuvel Pharmaceuticals Total Receivables Related Terms

Clinuvel Pharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Clinuvel Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinuvel Pharmaceuticals Total Receivables Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.09 16.20 22.22 26.24 27.46

Clinuvel Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.08 26.24 16.29 27.46 16.58
ASX:CUV
86GF Score
Clinuvel Pharmaceuticals Ltd ASX:CUV
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clinuvel Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$16.58 Mil mean?
Clinuvel Pharmaceuticals (ASX:CUV) has a Total Receivables of A$16.58 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Clinuvel Pharmaceuticals and its competitors.
Is Clinuvel Pharmaceuticals' Total Receivables too high?
Clinuvel Pharmaceuticals' current Total Receivables is A$16.58 Mil. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Total Receivables compare to VRTX and REGN?
Clinuvel Pharmaceuticals' Total Receivables of A$16.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current Total Receivables is A$16.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.73, compared to a current price of A$10.25 — trading 42.2% below its estimated fair value. The current Total Receivables is A$16.58 Mil. Clinuvel Pharmaceuticals' overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Total Receivables is A$16.58 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of A$10.25 is trading 42.2% below its estimated GF Value™ of A$17.73. GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ASX:CUV:

  • Total Receivables: A$16.58 Mil
  • GF Value™: A$17.73 vs. price of A$10.25 (42.2% below fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
86GF Score

Get the complete analysis for ASX:CUV

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$10.25
Price
A$17.73
GF Value